Published: March 10, 2010
Madeira Therapeutics Selected to Present at the 2010 World's Best Technologies Showcase
LEAWOOD, Kan. - (BUSINESS WIRE) - Madeira
Therapeutics, a Kansas-based company specializing in pediatric
pharmaceuticals, is one of over 100 companies and technology
innovators from across the nation and around the world that will compete
for top honors at the 2010 World's Best Technologies (WBT) Showcase,
March 16-17, in Arlington, Texas.
Madeira Therapeutics currently has two pediatric products in
development: MT-001, the first ever liquid preparation of a
cholesterol-lowering statin
for children and the elderly, and MT-003, a liquid analgesic for the
treatment of acute pain.
"Companies presenting at the WBTshowcase
leave with new knowledge and contacts to take their technologies to the
market and beyond," said WBTshowcase CEO Paul Huleatt. "The conventional
wisdom for venture capital is that a down economy can be a great time to
invest. The pace of new innovations accelerates, the best deals rise
quickly to the top and sophisticated investors receive great value for
their money."
Madeira Therapeutics' two pediatric products will be rigorously prepped
by WBTshowcase commercialization experts. Participating technologies are
selected by - and presented to - over 100 seasoned venture investors and
Fortune 500 licensing scouts representing a variety of industries, each
supported by private funding, federal R&D grants or both.
"With the rise of childhood obesity, the need for a pediatric statin is
critical," stated Madeira Therapeutics CEO Pete Joiner. "We are grateful
for the investors who are willing to join with us and address these
issues in our society today."
About Madeira Therapeutics
Madeira
Therapeutics, LLC, is a privately held, specialty pharmaceutical
company focused on providing safe and effective medicine to pediatric
and geriatric patients, parents and the healthcare professionals who
serve them. The Madeira strategy focuses on reformulating adult drugs
for better dosage control in children. Madeira utilizes the FDA's
505(b)(2) approval method, which relies in part on the regulatory
agency's findings for a drug previously approved for adults, thereby
shortcutting IND approval by years and saving tens of millions of
dollars in development costs. For more information, please visit http://www.madeiratherapeutics.com/.
Madeira Therapeutics
Pete Joiner, 913-661-1962
President/CEO
pjoiner@madeiratherapeutics.com
or
Media:
SCORR
Marketing
Kelly Sladek, 308-237-5567
kelly@scorrmarketing.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
